The study is assessing InVue for in vivo imaging and InForm for ex vivo imaging with 25 of targeted 50 patients imaged Study to support US FDA submission for both devices expected in H2 CY26 along ...
Host Tylah Tully sits down with Optiscan CEO and managing director Dr Camile Farah to discuss progress in the company’s breast cancer imaging study and why reaching the halfway mark is an important ...
Tylah Tully sits down with Optiscan CEO and managing director Dr Camile Farah to discuss the latest milestone in the company’s robotic surgery collaboration with the Mayo Clinic. Dr Farah explains the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results